← Analyst Upside
AU · rank #7 · 2026-06-04
LEGN
NASDAQ · $6.74B
verdict · CAUTION
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.989 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.12 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.177 |
| Analyst upside Consensus target $55.39 | +54.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +85.04% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.45 |
| Gross margin TTM | +20.0% |
| 52w high | $45.30 |
| Market cap | $6.74B |
The AI research card
Independent qualitative review of each pick before the order is placed.
Summary
Legend Biotech Corp is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer treatment.
Rationale
The quant model indicates strong analyst upside potential with a high revision agreement and significant momentum acceleration, suggesting positive sentiment among analysts.
Material risks
- 1The company has no recent insider buying activity, which may indicate a lack of confidence from insiders.
- 2Limited analyst coverage (only three analysts) could lead to volatility in stock price based on small changes in sentiment.
Verdict reasoning
two_stage score=+1/3 verdicts={'openai': 'PROCEED', 'claude': 'CAUTION', 'gemini': 'CAUTION'} brief=caller-supplied